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1. Introduction
The number of patients undergoing noncardiac surgery worldwide is growing, and annually
500,000 to 900,000 of these patients experience perioperative cardiac death, nonfatal perioper‐
ative myocardial infarction (PMI) or cardiac arrest [1]. Over 300,000 surgical revascularization
procedures are performed in the US annually as part of the treatment of expanding abdominal
aortic aneurysms, critical limb ischemia, and severe carotid disease [2].
The preoperative assessment of a patient in need of elective non-cardiac surgery is often
a difficult  task.  Current  guidelines  consider  vascular  surgery a  high-risk operation with
an anticipated risk of major postoperative cardiac complications in excess of 5% [3].  Al‐
though  the  reasons  relate,  in  part,  to  the  hemodynamic  stresses  associated  with  aortic
procedures,  the  prevalence  of  atherosclerotic  coronary  artery  disease  (CAD)  in  patients
undergoing vascular surgery exceeds 50% and therefore, may require special attention in
the preoperative period [4].
2. Pathophysiology of postoperative myocardial infarction
Unlike spontaneous myocardial infarction the majority of postoperative, or type 2, myocardial
infarctions (PMI) are thought to result from an imbalance between oxygen supply and demand
in the setting of severe, yet stable, coronary artery disease [5]. Several studies using continuous
electrocardiographic monitoring in high-risk vascular patients undergoing surgery have
shown that tachycardia-related ST-segment depression is common in the postoperative period
and is associated with in-hospital as well as long-term mortality [6-7]. Peak troponin elevation
correlates well with duration of ST-segment depression [8].
© 2013 Garcia and McFalls; licensee InTech. This is an open access article distributed under the terms of the
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Angiographic and Autopsy Data: In a landmark angiographic study Hertzer et al. showed
that only 8% of patients with peripheral arterial disease in need of major vascular surgery have
normal coronary arteries [4]. In the CARP trial, among 1048 patients undergoing coronary
angiography within 6-months of a high-risk vascular operation, the extent and severity of CAD
were predictors of long-term mortality (Figure 1) [9].
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Figure 1. Extent of Coronary Artery Disease and Survival
The prevalence of  angiographic chronic total  occlusions in patients  with PMI or cardiac
death is  81% as  opposed to  only  29% of  matched control  patients  without  PMI or  car‐
diac death [10]. On average patients with postoperative cardiac complications have 2 ±1.4
critical  (>70%)  coronary  stenosis  in  contrast  to  patients  without  postoperative  complica‐
tions who have less  disease burden (0.7  ±1.2).  Two small  autopsy studies reported con‐
flicting  data  on  the  incidence  of  coronary  plaque  rupture  in  patients  with  fatal  PMI
[11-12]. Dawood et al. found plaque rupture in only 7% of 42 autopsied patients [11]. In
contrast,  Cohen et  al.  reported in  a  smaller  study a  higher  incidence of  plaque rupture
(46%) [12].  Differences between studies could be explained on the basis of timing of the
autopsy relative to occurrence of PMI.
Stepwise approach to preoperative risk assessment:
The approach to  assessing the  potential  cardiac  risk  associated with  any patient  sched‐
uled for  elective  non-cardiac  operation includes  the  nature  of  the  operation,  the  risk  of
associated coronary artery disease and the functional  capacity of  the patient.  The initial
evaluation requires an assessment of a prior history of cardiac problems and/or risk fac‐
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tors along with either classical angina or unusual symptoms such as shortness of breath
or  atypical  chest  pains.  Attention should be  given to  clinical  risk  variables  such as  age
>70  years,  angina,  history  of  congestive  heart  failure,  prior  myocardial  infarction,  prior
cerebrovascular accident (CVA) or transient  ischemic attack (TIA),  history of  ventricular
arrhythmias, diabetes mellitus (particularly insulin dependent), and abnormal renal func‐
tion  (Creatinine  >2.0  mg/dl)  [13]  (Table  1).  The  physical  examination  also  provides  key
insight  into  high risk  variable  and include a  chronic  debilitated state,  increased jugular
venous distention,  edema,  S3  gallop,  significant  aortic  stenosis  while  the 12-lead electro‐
cardiogram  provides  prognostic  information  related  to  the  presence  of  abnormal  Q-
waves  or  heart  rhythms  other  than  normal  sinus.  Assessing  the  functional  capacity  of
patients undergoing elective operations is an important ingredient to determining wheth‐
er a patient can withstand the rigors of a prolonged operation. In those patients who are
unable to achieve a 4-MET demand, a level compatible with routine daily activities, there
is  increased  risk  of  postoperative  events  and  additional  testing  may  be  warranted  (i.e.
stress  test).  The  presence  of  multiple  ischemic  segments  indicative  of  either  multivessel
coronary  artery  disease  or  left  main  disease  is  considered  high  risk  and  is  associated
with an increased risk of perioperative cardiac complications and reduced long-term sur‐
vival [14]. Ultimately, a combined approach of utilizing clinical variables associated with
stress-imaging tests is most cost-effective.
RCRI Derivation set (2893) Validation set (n=1422)
 Events Rate, 95% CI Events Rate, 95% CI
0 5/1071 0.5 (0.2-1.1) 2/488 0.4 (0.5-1.5)
1 14/1106 1.3 (0.7-2.1) 5/567 0.9 (0.3-2.1)
2 18/506 3.6 (2.1-5.6) 17/258 6.6 (3.9-10.3)
≥3 19/210 9.1 (5.5-13.8) 12/109 11 (5.8-18.4)
Table 1. The Revised Cardiac Risk Index (RCRI) can be used to risk-stratify patients prior to non-cardiac surgery with
regard to the risk of serious cardiac complications. Adapted from Lee et al. Circulation 1999; 100:1043-1049.
3. Preventive therapies
Therapies that have been proven to reduce PMI among patients undergoing non-cardiac
surgery include beta-blockers and statins.
Beta-blockers:
Mangano et al. reported a 6% absolute risk reduction in cardiac events at 6 months with
atenolol among 200 male veterans undergoing noncardiac surgery [15]. Poldermans et al.
reported  a  more  dramatic  30%  absolute  risk  reduction  with  bisoprolol  among  173  pa‐
tients  undergoing vascular  surgery  with  evidence  of  myocardial  ischemia  on stress  test
[16]. However, subsequent larger studies with metoprolol yielded negative results [17-19]
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(Table  2).  The  landmark  POISE  trial,  with  over  8300  patients  enrolled  showed  that  al‐
though extended-release metoprolol 200 mg reduces PMI by 26%, it  is associated with a
higher  risk  of  death  and  stroke.  For  every  1000  patients  treated  with  extended-release
metoprolol  15  non-fatal  myocardial  infarctions would be prevented but  5  strokes and 8
deaths  would  be  caused  by  it  [20].  Therefore,  the  POISE  trial  raised  serious  concerns
about the safety of injudicious administration of high-dose beta-blockers in the perioper‐
ative period.
Study Patients Intervention Findings
Mangano et al. [15]
200 Male veterans
undergoing non-
cardiac surgery
Atenolol begun in
hospital
Cardiac events at 6 months 0%
(drug) vs. 8% (placebo)
Poldermans et al. [16]
173 patients with
ischemia undergoing
vascular surgery
Bisoprolol 30 days
before surgery
Cardiac events 3.4 % (drug) vs. 34%
(placebo)
Yang et al. [17] 496 vascular surgerypatients
Metoprolol begun
before surgery
Cardiac events 10.2% (metoprolol)
vs. 12% (placebo) (p=NS)
Juul et al. [18]
921 patients with
diabetes undergoing
major non-cardiac
surgery
Metoprolol XL 100 mg 21 % vs. 20% (p=NS)
Brady et al. [19]
103 patients without
previous MI
undergoing infrarenal
vascular surgery
Oral metoprolol 50 mg
bid 34 % vs. 30% (p=NS)
Devereaux et al. [20] 8351 undergoing non-cardiac surgery
Oral CR- metoprolol
200 mg/d for 30 days
5.8% (drug) vs. 6.9% (placebo).
Reduction in MI but increased risk of
stroke and mortality with
metoprolol
Table 2. Summary of clinical trials assessing the role of beta-blockers prior to non-cardiac surgery.
Statins:
In the Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiogra‐
py (DECREASE-III)  study high-dose fluvastatin reduced the composite of cardiovascular
death and non-fatal myocardial infarction by 53% among 457 patients undergoing vascu‐
lar surgery [21].  In a smaller  trial  involving 100 vascular patients randomly assigned to
20  mg  of  atorvastatin  or  placebo,  statins  reduced  cardiac  events  from  26%  to  8%  at  6
months [22]. In a single center registry of patients undergoing vascular operations at our
institution  the  use  of  perioperative  statins  was  an  independent  predictor  of  long-term
survival [23]. Statins may play a pivotal role in plaque stabilization by reducing circulat‐
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ing levels of inflammatory cytokines, increase expression of nitric oxide synthase, and re‐
duced production of endothelin-1 and reactive oxygen species.
Role of coronary revascularization:
The Coronary Artery Prophylactic Revascularization trial (CARP) showed that a strategy of
prophylactic revascularization was not superior to optimal medical therapy in preventing
PMIs or improving long-term mortality among 510 Veterans undergoing elective major
vascular surgery [24] (Figure 2). Despite high utilization rates of statins and beta-blockers in
the CARP trial, 16% of patients suffered a PMI [24]. Moreover, among patients with multiple
risk factors and/or evidence of myocardial ischemia on nuclear imaging test the incidence of
PMI was 25% [25], which was unaffected by revascularization status (Figure 3). Similarly to
CARP, the DECREASE-V pilot study failed to show any benefit with prophylactic revascula‐
rization among 101 patients with multivessel CAD and abnormal stress test prior to vascular
surgery (death or MI at 1 year 49% vs. 44%) [26]. These high events rates despite optimal
medical therapy highlight the need for additional interventions for risk reduction among high-
risk patients.
Reproduced from The New England Journal of Medicine 2004; 351:1795-804
Figure 2. Primary Outcome of the Coronary Artery Revascularization Prophylaxis (CARP) Trial
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Figure 3. Impact of Revascularization According to Number of Risks Enumerated in the Revised Cardiac Risk Index
4. Diagnosis
A joint ESC/ACCF/AHA/WHF Task Force has redefined myocardial infarction as an event
characterized by ischemic symptoms (i.e. chest pain or dyspnea), a typical rise and fall of
cardiac biomarkers (preferably troponin) with at least one value above the 99th percentile of
the upper reference limit, and electrocardiographic (ECG) changes consistent with myocardial
ischemia or imaging evidence of new loss of viable myocardium (i.e. new perfusion defect) or
wall motion abnormality [27].
Although this definition is useful for distinguishing spontaneous coronary events (Type I MI)
from events that arise at the time of coronary revascularization (Type 4 and 5 MIs), it does not
take into account unique features of perioperative myocardial infarctions after noncardiac
operations. First, the majority of coronary events that occur in the post-operative period are
clinically silent as a result of sedation and analgesia. In a post-hoc analysis of the POISE trial
65.3% of all patients with an MI did not have any ischemic symptoms [28]. Second, the ECG
is insensitive, relative to cardiac troponins, to detect myocardial ischemia in the post-operative
period [29]. Finally, after vascular surgery the presence of ischemic ECG changes does not
provide additional prognostic information regarding long-term mortality over and above that
provided by a single peak troponin I measured within 48 hours after vascular surgery [30].
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Our group, and others [31], has shown that cardiac troponins measured after surgery are
independent predictors of 30-day and long-term mortality [32] (Figure 4).
Group 0 (blue) normal, Group 1 (red) cTnI > 99th percentile but < 3 URL, Group 2 (orange) cTnI ≥ 3 URL. Adapted from
Journal of Vascular Surgery. In Press.
Figure 4. Kaplan-Meier estimates of mortality after vascular surgery relative to peak cardiac troponin I levels within 72
hours post-surgery
Taken together, these observations emphasize the importance of widespread utilization of
cardiac troponin in the perioperative period for the surveillance of myocardial infarction and
risk-stratification.
5. Treatment
Although robust data from randomized clinical trials is lacking small studies have shown that
interventions aimed at improving oxygen delivery and minimizing myocardial oxygen
consumption are beneficial in this setting. The main goals of therapy are to prevent, or
minimize, wide fluctuations in blood pressure and heart rate through beta-blockade, analgesia,
and fluid administration with the intention to preserve optimal coronary perfusion pressure
during diastole.
Martinez et al. randomized 80 patients with prolonged (≥ 20 minutes) ischemia after vascular
surgery to beta-blockers, aspirin, nitrates and optimization of oxygen supply-demand balance
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or control. At 6 months, patients treated for ischemia had lower mortality relative to control
patients (8% vs. 20%). In the post-operative period treated patients had lower median troponin
values when compared to controls (3.3 ng/ml vs. 8.5 ng/ml) [33].
Anemia is an independent predictor of mortality after non-cardiac surgery in the elderly [34].
Blood transfusion improved survival in critically ill patients with CAD and hemoglobin < 10%
[35]. This benefit was not seen among patients without CAD or among patients with a
hematocrit > 25% with some studies reporting increased mortality and nosocomial infections
associated with blood transfusions in [36].
Cardiac evaluation:
Although there is no consensus in the community with regard to the type (invasive angiog‐
raphy vs. imaging) and timing (in-hospital vs. 4-6 weeks after discharge) of cardiac evaluation
after a PMI registry data suggest that only a minority of patients with elevated biomarkers
receive cardiac work-up after the event [37].
Given the high-risk of bleeding immediately after non-cardiac surgery the use of emergency cor‐
onary angiography and stenting is usually reserved for patients with hemodynamic instability,
ST-elevation or inability to control ischemic symptoms with medications. Among patients with
coronary stents it is important to consider stent thrombosis in the differential diagnosis if ische‐
mic symptoms develop after non-cardiac surgery, particularly if antiplatelet agents have been
prematurely discontinued prior to the operation [38,39]. These patients have a high mortality
rate and emergency coronary angiography with revascularization is appropriate.
6. Conclusions
Improving outcomes in this high-risk group of patients undergoing vascular surgery will
require a paradigm shift from widespread use of cardiac imaging and procedures in the
preoperative phase to rapid detection and management of cardiac complications in the post-
operative setting with routine surveillance of cardiac troponins and targeted interventions.
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